for a tomorrow
yet to be seen
Delivering our innovative oral medicines
to patients with limited treatment options for their smile.
about us
PRD Therapeutics is a drug discovery startup developing novel lipid metabolism regulators that are effective* in rare diseases that cause dyslipidemia.
We are developing oral first-in-class new drugs with PRD compounds, the world's first and only SOAT2 selective inhibitors.
We are developing not only for patients with rare diseases but also for patients with lifestyle diseases related to lipid disorder.
By developing new oral drugs, which is more convenient and less burdensome for patients, we will bring new drugs and smiles to patients and their families around the world.
*proved effective in animal studies
-
step 01
Our initial focus will be on patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disease that leads to lifelong severely elevated LDL-C that increases the risk of early-onset arteriosclerosis and life-threatening cardiovascular diseases at a young age. HoFH incidence rate reported 1 in 170-300,000, and the number of patients is 20,000 to 50,000 globally.
-
step 02
After development of our initial compound for HoFH, we plan to expand to a broader population of patients with metabolic dysfunction associated fatty liver disease (MASH/MASLD, formerly NASH/NAFLD) who have a high risk for future cirrhosis and liver cancer. The prevalence of MASLD is over 30% globally.
-
step 03
Ultimately, we plan to further expand to all lipid metabolism-related diseases, including common dyslipidemias.
pipeline
- target
- indication
- discovery
- lead optimization
- preclinical
- clinical
-
prd001
- soat2
- pcsk9
HoFH
MASH / MASLD
(NASH / NAFLD) -
prd002
- soat2
- pcsk9
HoFH
MASH / MASLD
(NASH / NAFLD) -
prd003
- soat2
LAL-D ...other
-
prd004
- pcsk9
Dyslipidemia..other
technology
-
01.Healthy person
-
02.person with disordered lifestyles
-
03.HoFH Patients
-
04.PRD001
company
- Company Name
- PRD Therapeutics, Inc.
- President and CEO
- Kanji Hosoda
- Location
- Kitasato University Shirokane Campus 1506, 5-9-1
Shirokane, Minato-ku, Tokyo 108-0072 Japan
history
- soat
- prd
- soat
-
1980
SOAT (formerly ACAT) inhibitors were being developed as potential post-statin drugs.
-
1993
(1993-1998)SOAT isozymes, SOAT1/SOAT2, were reported.
-
1996
(1996-2000)SOAT1 KO mouse was reported.
SOAT1 KO mouse showed phenotypic toxicities such as increased atherosclerotic lesions, adrenal cortex abnormalities, and massive anthomatosis. -
2000
(2000-2003)SOAT2 KO mouse was reported.
SOAT2 KO mouse showed phenotypes such as decrease of CE synthesis in the small intestine and liver, improvement of arteriosclerosis and fatty liver that have not been observed in SOAT1 KO mice, suggesting that a highly SOAT2-selective inhibitor is efficacious. -
2003
(2003-2005)SOAT1/2 dual inhibitors, avasimibe and pactimibe, were determined to discontinue clinical trials due to adverse events such as increased LDL-C levels and incidence of cardiovascular events.
Those adverse events have been found in SOAT1 KO mouse, suggesting that they were due to SOAT1 inhibition. -
2021
(2021-2022)SOAT2 KO mouse demonstrated effective for MASH/MASLD.
- prd
-
1993
Prof. Tomoda (co-founder of PRD) et al. discovered pyripyropene A (PPPA) from the fungal culture broth prepared at Kitasato Institute.
-
2003
PPPA was discovered to be the world's first and only SOAT2 selective inhibitor.
-
2007
Efficacy of PPPA was confirmed in animal experiments in mice.
-
2011
Lead optimization from PPPA to lead to PRD001 was completed.
-
2018
Efficacy of PRD001 was confirmed in animal experiments in mice, rabbits, and monkeys.
-
2021
PRD Therapeutics, Inc. was established.
-
2023
Series A round raising $10M was completed.
our member
-
hosoda kanji
CEO･Co-Founder
-
tomoda hiroshi
Outside director･Co-Founder, Professor, Ph.D.
-
mishima tetsuya
Director
-
mori fumitaka
Outside director, Ph.D.
-
kobayashi taira
Outside director, Ph.D.
-
setoyama hiroki
Outside auditor
